Non-Executive Board Member
Andreas Wallnöfer is General Partner at BioMedPartners, Basel, Switzerland and board member of several European biotech companies. He is a senior executive leader with more than 20 years of experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee.
He was Head of the Roche Pharma Cardiovascular & Metabolism Disease Area and left Roche in 2015 after the company strategically decided to exit these research areas. At Roche, Andreas was part of several successful product development programs and market introductions. As Head of Clinical Research & Exploratory Development he and his groups were involved in the due diligence evaluations for in-licensing projects and product acquisitions for several years. He had a key role in the integration of the Roche and Genentech Development organizations and led subsequently Roche’s Early Development Department, in addition to the Cardiovascular & Metabolism R&D unit.
Andreas holds a PhD in Pharmacology from the University of Basel and was trained as a fellow in Clinical Pharmacology at the University of Leiden, The Netherlands. He also holds an Executive MBA from IMD Lausanne.